The Use of DHEA in Women With Premature Ovarian Failure

This study has been withdrawn prior to enrollment.
(very poor patient recruitement)
Sponsor:
Information provided by (Responsible Party):
Fady I. Sharara, M.D, Virginia Center for Reproductive Medicine
ClinicalTrials.gov Identifier:
NCT01129947
First received: May 23, 2010
Last updated: January 26, 2013
Last verified: January 2013

May 23, 2010
January 26, 2013
May 2010
January 2013   (final data collection date for primary outcome measure)
The Use of DHEA in Women With Premature Ovarian Failure [ Time Frame: 3 years ] [ Designated as safety issue: No ]
The following outcomes will be evaluated: FSH, AMH, estradiol, ovarian volume, antral follicle count, pregnancy in women seeking to conceive
Same as current
Complete list of historical versions of study NCT01129947 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Use of DHEA in Women With Premature Ovarian Failure
The Use of DHEA in Women With Premature Ovarian Failure

DHEA supplementation has been used in women with infertility and diminished ovarian reserve. There is a small report in 5 women with POF that benefited from the use of DHEA over several months. The investigators aim to evaluate further the use of DHEA in women with Premature ovarian failure (POF).

Not Provided
Interventional
Phase 0
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Premature Ovarian Failure
Drug: DHEA
DHEA 25 mg tid
Experimental: DHEA
Intervention: Drug: DHEA
Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol. 2009 Aug;21(4):306-8. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women with POF

Exclusion Criteria:

  • women without ovaries
Female
18 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01129947
VCRM4
Yes
Fady I. Sharara, M.D, Virginia Center for Reproductive Medicine
Virginia Center for Reproductive Medicine
Not Provided
Not Provided
Virginia Center for Reproductive Medicine
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP